These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Inflammatory, immune, and viral aspects of inclusion-body myositis. Dalakas MC Neurology; 2006 Jan; 66(2 Suppl 1):S33-8. PubMed ID: 16432143 [TBL] [Abstract][Full Text] [Related]
45. Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches. Needham M; Mastaglia FL Lancet Neurol; 2007 Jul; 6(7):620-31. PubMed ID: 17582362 [TBL] [Abstract][Full Text] [Related]
46. Reducing body myopathy with cytoplasmic bodies and rigid spine syndrome: a mixed congenital myopathy. Goebel HH; Halbig LE; Goldfarb L; Schober R; Albani M; Neuen-Jacob E; Voit T Neuropediatrics; 2001 Aug; 32(4):196-205. PubMed ID: 11571700 [TBL] [Abstract][Full Text] [Related]
47. Multiple mitochondrial DNA deletions in sporadic inclusion body myositis: a study of 56 patients. Santorelli FM; Sciacco M; Tanji K; Shanske S; Vu TH; Golzi V; Griggs RC; Mendell JR; Hays AP; Bertorini TE; Pestronk A; Bonilla E; DiMauro S Ann Neurol; 1996 Jun; 39(6):789-95. PubMed ID: 8651651 [TBL] [Abstract][Full Text] [Related]
48. Inclusion body myositis: from genetics to clinical trials. Nagy S; Khan A; Machado PM; Houlden H J Neurol; 2023 Mar; 270(3):1787-1797. PubMed ID: 36399165 [TBL] [Abstract][Full Text] [Related]
49. Proposed pathogenetic cascade of inclusion-body myositis: importance of amyloid-beta, misfolded proteins, predisposing genes, and aging. Askanas V; Engel WK Curr Opin Rheumatol; 2003 Nov; 15(6):737-44. PubMed ID: 14569203 [TBL] [Abstract][Full Text] [Related]
50. Sporadic inclusion body myositis--diagnosis, pathogenesis and therapeutic strategies. Dalakas MC Nat Clin Pract Neurol; 2006 Aug; 2(8):437-47. PubMed ID: 16932602 [TBL] [Abstract][Full Text] [Related]
51. Proteasomal expression, induction of immunoproteasome subunits, and local MHC class I presentation in myofibrillar myopathy and inclusion body myositis. Ferrer I; Martín B; Castaño JG; Lucas JJ; Moreno D; Olivé M J Neuropathol Exp Neurol; 2004 May; 63(5):484-98. PubMed ID: 15198127 [TBL] [Abstract][Full Text] [Related]
52. [Inclusion body myositis]. Bodoki L; Vincze M; Griger Z; Csonka T; Dankó K; Hortobágyi T Ideggyogy Sz; 2015 Jan; 68(1-2):59-67. PubMed ID: 25842918 [TBL] [Abstract][Full Text] [Related]
53. Late-onset myopathies: clinical features and diagnosis. de Visser M Acta Myol; 2020 Dec; 39(4):235-244. PubMed ID: 33458579 [TBL] [Abstract][Full Text] [Related]
54. Sensitivity and clinical utility of the anti-cytosolic 5'-nucleotidase 1A (cN1A) antibody test in sporadic inclusion body myositis: Report of 40 patients from a single neuromuscular center. Felice KJ; Whitaker CH; Wu Q; Larose DT; Shen G; Metzger AL; Barton RW Neuromuscul Disord; 2018 Aug; 28(8):660-664. PubMed ID: 30001928 [TBL] [Abstract][Full Text] [Related]
55. Inclusion body myositis: therapeutic approaches. A case report. Kierdaszuk B; Kamińska A Neurol Neurochir Pol; 2011; 45(1):68-73. PubMed ID: 21384296 [TBL] [Abstract][Full Text] [Related]
56. Pathophysiology of inflammatory and autoimmune myopathies. Dalakas MC Presse Med; 2011 Apr; 40(4 Pt 2):e237-47. PubMed ID: 21411269 [TBL] [Abstract][Full Text] [Related]